** WARNING, Not error free yet, under construction: check result to a standard work. **
Difference between revisions of "Quetiapine"
From MedicaWiki
| [checked revision] | [checked revision] |
| Line 36: | Line 36: | ||
| cth = 50-500 | | cth = 50-500 | ||
| cth_ref = {{UMCGTox}} | | cth_ref = {{UMCGTox}} | ||
| − | | price = | + | | price = 3 |
| − | | price_ref = <ref>oraal | + | | price_ref = <ref>oraal 95,10/maand/DDD cf FTK: results in €3.17 </ref> |
| <!-- caution areas --> | | <!-- caution areas --> | ||
Revision as of 09:12, 23 May 2011
| quetiapine | |||||||||||||||||||||||
| Type | antipsychotic | ||||||||||||||||||||||
| Group | atypical antipsychotics | ||||||||||||||||||||||
| links | |||||||||||||||||||||||
| ATC-code | N05AH04 | ||||||||||||||||||||||
| CAS-number | 111974-69-7 | ||||||||||||||||||||||
| Medscape | 342984 | ||||||||||||||||||||||
| PubChem | 5002 | ||||||||||||||||||||||
| PubMed | quetiapine | ||||||||||||||||||||||
| Drugs.com | quetiapine-fumarate | ||||||||||||||||||||||
| drugbank | APRD00675 | ||||||||||||||||||||||
| Kompas (nl) | quetiapine | ||||||||||||||||||||||
| Wikipedia | quetiapine | ||||||||||||||||||||||
| |||||||||||||||||||||||
quetiapine is an antipsychotic in the group atypical antipsychotics.
| Caution area | Value | Ref | Description |
|---|---|---|---|
| Lactation | 6 | [9] | Possibly unsafe |
| Pregnancy | 5 | [5] | possibly unsafe - B3* - animal studies have shown fetal damage, significance in humans unknown |
| Diabetes mellitus | 6 | [7][10][11] | average influence on diabetes - frequent monitoring recommended |
| Hepatic insufficiency | 8 | [5] | Unsafe with mild hepatic impairment (Child-Pugh classification A - monitoring required) |
| Children | 2 | [12] | applicable - not registered for pediatric use, but well studied |
| Elderly | 6 | [5][10][13] | average safety - adapt dosage |
| Dementia | 10 | [10] | not approved for patients with dementia |
| Chronic Obstructive Pulmonary Disease | 8 | [14][15] | unsafe - adapt dosage or substitute drug |
| Hypertension | 8 | [6] | common (between 1 in 10 and 1 in 100 patients: 1% - 10%) |
| Hypotension | 8 | [6][10] | common (between 1 in 10 and 1 in 100 patients: 1% - 10%) |
| Heart failure | 8 | [6] | strong influence on HF - rather unsafe, continue only if absolutely necessary |
| Long QT-syndrome | 4 | [5][16][17] | Possible Risk of QT prolongation Arizona Scale - Possible Risk of TdP |
| Seizures | 6 | [7][10] | uncommon (between 1 in 100 and 1 in 1,000 patients: 0,1% - 1%) |
| Cerebrovascular accidents | 8 | [6][7] | strong influence on CVA - only applicable with frequent monitoring |
| Renal insufficiency | 6 | [18][19] | unsafe when MDRD between 30 - 50 (moderate renal impairment, monitoring required) |
| Dyskinesia | 8 | [6][13] | common (between 1 in 10 and 1 in 100 patients: 1% - 10%) |
| Movement disorders | 10 | [6][10] | very common (over 1 in 10 patients: > 10%) |
| Haematology | 8 | [5][6][10] | common (between 1 in 10 and 1 in 100 patients: 1% - 10%) |
| Anticholinergic effects | 10 | [5][6][7] | very common (over 1 in 10 patients: > 10%) |
| Male sexual dysfunction | 10 | [20][22] | very common (over 1 in 10 patients: > 10%) |
| Female sexual dysfunction | 10 | [20][22] | very common (over 1 in 10 patients: > 10%) |
| Traffic | 6 | [5][23] | medium influence (category II) 0,5-0,8 g/l (0,5–0,8‰) |
| Weight | 10 | [10][24][25][26] | very common (over 1 in 10 patients: > 10%) |
| Weight gain | 0 | unknown/unverified | |
| Weight loss | 0 | unknown/unverified | |
| Photosensitivity | 0 | unknown/unverified | |
| Sedation | 10 | [21] | very common (over 1 in 10 patients: > 10%) |
| Poor CYP2D6 metabolizer | 0 | unknown/unverified | |
| Ultra rapid CYP2D6 metabolizer | 0 | unknown/unverified | |
| Poor CYPC19 metabolizer | 0 | unknown/unverified | |
| Ultra rapid CYP2C19 metabolizer | 0 | unknown/unverified |
- ↑ WHO Collaborating Centre for Drug Statistics Methodology ATC=N05AH04
- ↑ Universitair Medisch Centrum Groningen, Referentiewaarden klinisch farmacologisch bepalingen
- ↑ NVZA; Toxicology.org; Monografie ID=73 (dutch)
- ↑ Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics; J Clin Psychiatry 2003; 64: 663-667 (pubmed-id 12823080)
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 KNMP; Informatorium Medicamentorum 2009; Monografie "quetiapine" (Dutch)
- ↑ 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 Drugs.com quetiapine-fumarate
- ↑ 7.0 7.1 7.2 7.3 7.4 CVZ; Farmacotherapeutisch Kompas - quetiapine (dutch)
- ↑ oraal 95,10/maand/DDD cf FTK: results in €3.17
- ↑ Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk, 8th edition. Lippincott Williams & Wilkins; 2008
- ↑ 10.0 10.1 10.2 10.3 10.4 10.5 10.6 10.7 10.8 AstraZeneca; SPC SEROQUEL * 25 mg, 100 mg, 150 mg, 200 mg, 300 mg film-coated tablets
- ↑ Bazire S. Psychotropic drug directory 2007. Trowbridge: Cromwell Press; 2007
- ↑ NKFK Kinderformularium ID=649 (dutch)
- ↑ 13.0 13.1 Yang CH, Tsai SJ, Hwang JP. The efficacy and safety of quetiapine for treatment of geriatric psychosis. J Psychopharmacol. 2005 Nov;19(6):661-6 (pubmed-id 16272189)
- ↑ Jabeen S, Polli SI, Gerber DR. Acute respiratory failure with a single dose of quetiapine fumarate. Ann Pharmacother. 2006 Mar; 40(3): 559-62. Epub 2006 Feb 7. (pubmed-id 16467251)
- ↑ Trifirò G, Gambassi G, Sen EF, Caputi AP, Brea J, Sturkenboom MC. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med 2010; 152(7): 418-25 (pubmed-id 20368647)
- ↑ Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation; Int Clin Psychopharmacol 2005; 20: 243-251 (pubmed-id 16096514)
- ↑ Arizona Scale
- ↑ Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines, 10th edition. London: Informa Healthcare; 2009
- ↑ Bazire S. Psychotropic drug directory 2007. Trowbridge: Cromwell Press; 2007
- ↑ 20.0 20.1 20.2 KNMP; Informatorium Medicamentorum 2009; Inleidende tekst "Atypische Antipsychotica" (Dutch)
- ↑ 21.0 21.1 ToxNet, Hazardous Substances Data Bank - 7557
- ↑ 22.0 22.1 Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol. 2011 May;26(3):130-40 (pubmed-id 21191308)
- ↑ The International Council on Alcohol, Drugs and Traffic Safety (ICADTS). ICADTS drug list - July 2007 (Internet)
- ↑ Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007;68(suppl 1): 20-7 (pubmed-id 17286524)
- ↑ Cahn W, Ramlal D, Bruggeman R, de Haan L, Scheepers FE, van Soest MM et al. Prevention and treatment of somatic complications arising from the use of antipsychotics. Tijdschr Psychiatr 2008;50(9):579-91 (pubmed-id 18785105)
- ↑ Zheng L, Mack WJ, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry 2009; 166:583-90 (pubmed-id 19369318)
